Cargando…

The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic Cerebrovascular Disease

Ischemic cerebrovascular disease (ICD), the most common neurological disease worldwide, can be classified based on the onset time (acute/chronic) and the type of cerebral blood vessel involved (artery or venous sinus). Classifications include acute ischemic stroke (AIS)/transient ischemic attack (TI...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Siying, Wu, Hao, Ji, Xunming, Meng, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605177/
https://www.ncbi.nlm.nih.gov/pubmed/36294518
http://dx.doi.org/10.3390/jcm11206193
_version_ 1784818000446095360
author Song, Siying
Wu, Hao
Ji, Xunming
Meng, Ran
author_facet Song, Siying
Wu, Hao
Ji, Xunming
Meng, Ran
author_sort Song, Siying
collection PubMed
description Ischemic cerebrovascular disease (ICD), the most common neurological disease worldwide, can be classified based on the onset time (acute/chronic) and the type of cerebral blood vessel involved (artery or venous sinus). Classifications include acute ischemic stroke (AIS)/transient ischemic attack (TIA), chronic cerebral circulation insufficiency (CCCI), acute cerebral venous sinus thrombosis (CVST), and chronic cerebrospinal venous insufficiency (CCSVI). The pathogenesis of cerebral arterial ischemia may be correlated with cerebral venous ischemia through decreased cerebral perfusion. The core treatment goals for both arterial and venous ICDs include perfusion recovery, reduction of cerebral ischemic injury, and preservation of the neuronal integrity of the involved region as soon as possible; however, therapy based on the current guidelines for either acute ischemic events or chronic cerebral ischemia is not ideal because the recurrence rate of AIS or CVST is still very high. Therefore, this review discusses the neuroprotective effects of four novel potential ICD treatments with high translation rates, known as the BE COOL treatments (Batroxobin, oxygEn, Conditioning, and cOOLing), and subsequently analyzes how BE COOL treatments are used in clinical settings. The combination of batroxobin, oxygen, conditioning, and cooling may be a promising intervention for preserving ischemic tissues.
format Online
Article
Text
id pubmed-9605177
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96051772022-10-27 The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic Cerebrovascular Disease Song, Siying Wu, Hao Ji, Xunming Meng, Ran J Clin Med Review Ischemic cerebrovascular disease (ICD), the most common neurological disease worldwide, can be classified based on the onset time (acute/chronic) and the type of cerebral blood vessel involved (artery or venous sinus). Classifications include acute ischemic stroke (AIS)/transient ischemic attack (TIA), chronic cerebral circulation insufficiency (CCCI), acute cerebral venous sinus thrombosis (CVST), and chronic cerebrospinal venous insufficiency (CCSVI). The pathogenesis of cerebral arterial ischemia may be correlated with cerebral venous ischemia through decreased cerebral perfusion. The core treatment goals for both arterial and venous ICDs include perfusion recovery, reduction of cerebral ischemic injury, and preservation of the neuronal integrity of the involved region as soon as possible; however, therapy based on the current guidelines for either acute ischemic events or chronic cerebral ischemia is not ideal because the recurrence rate of AIS or CVST is still very high. Therefore, this review discusses the neuroprotective effects of four novel potential ICD treatments with high translation rates, known as the BE COOL treatments (Batroxobin, oxygEn, Conditioning, and cOOLing), and subsequently analyzes how BE COOL treatments are used in clinical settings. The combination of batroxobin, oxygen, conditioning, and cooling may be a promising intervention for preserving ischemic tissues. MDPI 2022-10-20 /pmc/articles/PMC9605177/ /pubmed/36294518 http://dx.doi.org/10.3390/jcm11206193 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Song, Siying
Wu, Hao
Ji, Xunming
Meng, Ran
The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic Cerebrovascular Disease
title The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic Cerebrovascular Disease
title_full The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic Cerebrovascular Disease
title_fullStr The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic Cerebrovascular Disease
title_full_unstemmed The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic Cerebrovascular Disease
title_short The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic Cerebrovascular Disease
title_sort be cool treatments (batroxobin, oxygen, conditioning, and cooling): emerging adjunct therapies for ischemic cerebrovascular disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605177/
https://www.ncbi.nlm.nih.gov/pubmed/36294518
http://dx.doi.org/10.3390/jcm11206193
work_keys_str_mv AT songsiying thebecooltreatmentsbatroxobinoxygenconditioningandcoolingemergingadjuncttherapiesforischemiccerebrovasculardisease
AT wuhao thebecooltreatmentsbatroxobinoxygenconditioningandcoolingemergingadjuncttherapiesforischemiccerebrovasculardisease
AT jixunming thebecooltreatmentsbatroxobinoxygenconditioningandcoolingemergingadjuncttherapiesforischemiccerebrovasculardisease
AT mengran thebecooltreatmentsbatroxobinoxygenconditioningandcoolingemergingadjuncttherapiesforischemiccerebrovasculardisease
AT songsiying becooltreatmentsbatroxobinoxygenconditioningandcoolingemergingadjuncttherapiesforischemiccerebrovasculardisease
AT wuhao becooltreatmentsbatroxobinoxygenconditioningandcoolingemergingadjuncttherapiesforischemiccerebrovasculardisease
AT jixunming becooltreatmentsbatroxobinoxygenconditioningandcoolingemergingadjuncttherapiesforischemiccerebrovasculardisease
AT mengran becooltreatmentsbatroxobinoxygenconditioningandcoolingemergingadjuncttherapiesforischemiccerebrovasculardisease